Earthnetmedia Inc Sample Contracts

Immunotech Laboratories, Inc. – IMMUNOTECH Laboratories Inc. (IMMB) announced today that it has signed a Special Private Placement Agreement (SPPA) for equity line funding with World Finance Capital Holdings Inc. (WFC) to obtain S-1 registration. (October 1st, 2013)

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or

Immunotech Laboratories, Inc. – Monrovia, Calif.---- 3/ 22, 2013--- Immunotech Laboratories, Inc. Immunotech Laboratories ,Inc. announce that the company signed an agreement with The Lebrecht Group a professional law corporation to provide legal services for Immunotech and to upgrade the company to current status. Further information can be obtained from www.immunotechlab.com (March 25th, 2013)

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or

Immunotech Laboratories, Inc. – Press Release Source: Immunotech Laboratories, Inc. ( IMMB ) (February 4th, 2013)

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the U.S. Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and the tests on t

Immunotech Laboratories, Inc. – Press Release Source: Immunotech Laboratories, Inc. ( IMMB ) (February 4th, 2013)

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or

Immunotech Laboratories, Inc. – Press Release Source: Immunotech Laboratories, Inc. ( IMMB ) (October 11th, 2012)

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or

Immunotech Laboratories, Inc. – Press Release Source: Immunotech Laboratories, Inc. ( IMMB ) (September 19th, 2012)

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or

Immunotech Laboratories, Inc. – Press Release Source: Immunotech Laboratories, Inc. ( IMMB ) (June 13th, 2012)

In March 2012, Immunotech Laboratories, Inc. and collectively the Zhabilov Group, entered into a binding Release and Settlement Agreement with Viral Genetics Inc. and collectively the Viral Group and its principals that was approved by the court. The Settlement ends the almost 5-year-old lawsuit between the parties, dismissing all claims without admission of liability by any party. The Company’s HIV/AIDS technology and the Zhabilov Group’s cancer therapeutics and detection technology intellectual property portfolio have grown considerably in these last five years. As a result, both the Company and the Zhabilov Group are now free to pursue possible partnerships and joint ventures at a much higher level that better reflect the value of the work. According to its President and Chief Science Officer, Harry Zhabilov, “with this arduous and time-consuming process behind, Immunotech Laboratories, Inc. is now completely free to focus on the development of new drug candidates”.

Immunotech Laboratories, Inc. – EXHIBIT A (January 5th, 2011)

This Agreement and Plan of Merger ("Agreement"), is made and entered into this 12th day of December 2008, by and among INTERNATIONAL TECHNOLOGY SYSTEMS, INC., a Nevada corporation ("ITSI"), IMMUNOTECH LABORATORIES, INC., a California corporation ("IMMUNOTECH”). ITSI, and IMMUNOTECH are hereinafter sometimes collectively referred to as the "Parties."

Immunotech Laboratories, Inc. – EXHIBIT D (January 5th, 2011)

This EXCLUSIVE SUB-LICENSING AGREEMENT ("Agreement"), effective as of April 2, 2009 (the "Effective Date"), is entered into by and among IMMUNOTECH LABORATORIES, INC. (“Immunotech”), a Nevada Corporation with its principal offices located at 116 W. Stocker Street, Glendale, California 91202 and VOLTAIRE ALBERTO GOMEZ RAMOS , (“Gomez”), a Mexican national resident of the State of Baja California, Mexico, domiciled at Tijuana, Baja California, Mexico, with a mailing address at P.O. Box 434307 , San Ysidro, California, 92143-4307, USA.

Immunotech Laboratories, Inc. – EXHIBIT D (January 5th, 2011)

This EXCLUSIVE SUB-LICENSING AGREEMENT ("Agreement"), effective as of April 2, 2009 (the "Effective Date"), is entered into by and among IMMUNOTECH LABORATORIES, INC. (“Immunotech”), a Nevada Corporation with its principal offices located at 116 W. Stocker Street, Glendale, California 91202 and VOLTAIRE ALBERTO GOMEZ RAMOS , (“Gomez”), a Mexican national resident of the State of Baja California, Mexico, domiciled at Tijuana, Baja California, Mexico, with a mailing address at P.O. Box 434307 , San Ysidro, California, 92143-4307, USA.

Immunotech Laboratories, Inc. – EXHIBIT B EXCLUSIVE LICENSING AGREEMENT (January 5th, 2011)

This EXCLUSIVE LICENSING AGREEMENT (“Agreement”), effective as of September 1, 2008 (the “Effective Date”), is entered into by and among DANIEL ZHABILOV as Trustee of The Zhabilov Trust, a California Trust executed at Los Angeles, California on March 2, 2006 (“The Zhabilov Trust”) and IMMUNOTECH LABORATORIES, INC., a California corporation (“Immunotech”), with its principal offices located at ….

Immunotech Laboratories, Inc. – EXECUTIVE SUMMARY (December 16th, 2010)

Immunotech Laboratories Inc. is an organization with full indefinite licensing rights of the Irreversible Pepsin Fraction (IPF) peptide molecule for the specific treatment and preventing of the HIV/AIDS indication. IPF is a peptide molecule that has a s affinity to bind with the HIV virus’ peptide components identified as gp41 and gp120 antigens, rendering them as super antigens, and taking away from them their stealthiness and their capability to destroy the immune system.

Immunotech Laboratories, Inc. – Contract (December 10th, 2010)

Congressman Danny K. Davis (Il-7th) submitted House Resolution 1179, legislation that puts Congress on record in supporting biotechnology firms that meet small business standards, their intellectual property, the importance of the impact of various innovative therapies to treat a variety of life threatening conditions, including pandemic diseases. Immunotech Laboratories, Inc. (IMMB), which is developing a unique Immune Therapeutic treatment for HIV/AIDS along with a group of other Biotech companies, has taken an active role supporting the legislation and actively working for its eventual passage. The legislation encourages Federal agencies to develop a coordinated, national approach to the small biotechnology sector to develop and coordinate resources and funding mechanisms to preserve and enhance the survival of these firms. The resolution can be found online at http://thomas.gov/cgi-bin/query/z?c111:H.RES.1179: or in the text below.

Immunotech Laboratories, Inc. – AGREEMENT FOR MEMBER OF THE SCIENTIFIC ADVISORY COMMITTEE (March 16th, 2010)

THIS AGREEMENT is made and entered into effective as of May 18, 2009(the "Effective Date"), by and between Immunotech Laboratories Inc., a Nevada corporation, ("Company") and Mariel Selbovitz an individual ("Advisor").

Immunotech Laboratories, Inc. – [WHITECOAT LOGO] Washington, DC 20003 AGENCY AGREEMENT (March 16th, 2010)

This Agreement is made this 6th day of July, 2009, between WHITECOAT LLC, a Washington, DC company ("Agency") with offices at 908 Pennsylvania Ave. SE, Washington, DC and Immunotech Labs with offices in 116 W. Stocker Street, Glendale, California (“Client"). The parties agree as follows:

Immunotech Laboratories, Inc. – Contract (March 16th, 2010)

THIS MASTER AGREEMENT (“the Agreement”) sets forth the terms and conditions of services to be provided by Symbion Research International, Inc., a California corporation with its principal place of business located at 3537 Old Conejo Road, Suite 115, Newbury Park, CA 91320, hereinafter referred to as “Symbion”, to Immunotech Laboratories, with its principal place of business located at 116 West Stocker Street, Glendale, CA, 91202, hereinafter referred to as “Client.” This Agreement is made effective as of the 30th day of July 2009 by and between Symbion and Client.

Immunotech Laboratories, Inc. – AGREEMENT FOR MEMBER OF THE BOARD OF DIRECTORS (March 16th, 2010)

THIS AGREEMENT is made and entered into effective as of May 18, 2009(the "Effective Date"), by and between Immunotech Laboratories Inc., a Nevada corporation, ("Company") and Dr. Roscoe M. Moore Jr. an individual ("Director").

Immunotech Laboratories, Inc. – AGREEMENT FOR MEMBER OF THE SCIENTIFIC ADVISORY COMMITTEE (March 16th, 2010)

THIS AGREEMENT is made and entered into effective as of July 7, , 2009 (the "Effective Date"), by and between Immunotech Laboratories Inc., a Nevada corporation, ("Company") and Joel L. Zive an individual ("Advisor").

Immunotech Laboratories, Inc. – AGREEMENT AND PLAN OF MERGER (March 13th, 2009)

This Agreement and Plan of Merger ("Agreement"), is made and entered into this 12th day of December 2008, by and among INTERNATIONAL TECHNOLOGY SYSTEMS, INC., a Nevada corporation ("ITSI"), IMMUNOTECH LABORATORIES, INC., a California corporation ("IMMUNOTECH”). ITSI, and IMMUNOTECH are hereinafter sometimes collectively referred to as the "Parties."

Immunotech Laboratories, Inc. – AGREEMENT RE CONSIDERATION FOR LICENSING OF PATENT (March 13th, 2009)

This agreement is irrevocable and can not be reversed or changed without the strict written agreement of both Harry H. Zhabilov and Ara A. Ghanime. Furthermore this agreement will be rendered void and all licensing rights will be reversed and terminated if any of this agreement’s conditions are not met.

Earthnetmedia Inc – CERTIFICATE OF AMENDMENT (July 26th, 2005)
Earthnetmedia Inc – SECURITY AGREEMENT (August 14th, 2002)

EXHIBIT 10.11 SECURITY AGREEMENT THIS SECURITY AGREEMENT, dated as of July 1, 2002, is made by EarthNetMedia, Inc., a Nevada corporation ("Borrower") in favor of Alie Chang and Felizian Paul, husband and wife (together, "Lender"). WHEREAS, Borrower has received advances and loans and other extensions of credit from time to time from Lender (including without limitation deferral of salary obligations and rent), certain of which are evidenced by a promissory note of even date herewith (as the same may be amended, modified, supplemented, renewed or replaced from time to time, the "Note") and Borrower expects to receive additional extensions of credit of similar natures from Lender in the future; and NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Borrower hereby agrees as follows:

Earthnetmedia Inc – PROMISSORY NOTE (August 14th, 2002)

EXHIBIT 10.9 EARTHNETMEDIA, INC. PROMISSORY NOTE FOR VALUE RECEIVED, EarthNetMedia, Inc. (the "Maker"), promises to pay to Fujiwara Capital Corp, a Nevada corporation (the "Payee"), and to its successors and assigns, the principal sum of thirty-seven thousand five hundred dollars ($37,500), together with interest on the unpaid principal balance at a rate of eight percent (8%) per year. Payment of principal and interest shall be made out of ten percent (10%) of the proceeds realized by the Maker from the sale of its common stock after the date hereof pursuant to the exercise of warrants outstanding as of the date hereof. Payment of principal and interest under this Note shall be made in lawful money of the United States of America to the Payee at the address which is set forth below or to such other location as shall be designated to the Ma

Earthnetmedia Inc – DEMAND PROMISSORY NOTE (August 14th, 2002)

EXHIBIT 10.10 DEMAND PROMISSORY NOTE $500,000.00 Dated: as of July 1, 2002 1. PRINCIPAL. FOR VALUE RECEIVED, the undersigned, EarthNetMedia, Inc., a Nevada corporation ("Borrower"), hereby promises to pay to the order of Alie Chang and Felizian Paul (together, "Lender") the principal sum of Five Hundred Thousand United States Dollars and No Cents (U.S.$500,000.00), or so much thereof as shall have been disbursed to Borrower, as reflected in the Schedule annexed to this Note (the "Loan") with interest from the date of this Note on the unpaid principal at the rate of eight percent (8%) per annum. 2. SCHEDULE TO NOTE. Borrower hereby authorizes Lender to endorse on the Schedule annexed to this Note all loans made to Borrower and all payments of principal amounts in respect of such loans, whi

Earthnetmedia Inc – FINAL AGREEMENT (March 29th, 2002)

EXHIBIT 10.7 FINAL AGREEMENT THIS AGREEMENT is entered into on the 10th day of January, 2002 between EarthNetMedia, Inc., a Nevada corporation ("EarthNetMedia" or the "Company") and International Financial Consultants, S.A. ("IFC"). WITNESSETH: WHEREAS, EarthNetMedia filed a Form SB-2 by which the Company offered to sell 100,000 Units to the public, and, WHEREAS, a Unit consists of one share of Common Stock and forty Common Stock Purchase Warrants, and, WHEREAS, EarthNetMedia desires to engage IFC to market EarthNetMedia's common stock resulting from the conversion of EarthNetMedia's Warrants, and, WHEREAS, IFC agrees to be engaged by EarthNetMedia to perform the task(s) enumerated heretofore, NOW THEREFORE, for good and valuable consideration the receipt and sufficiency of which is herein acknowledged, EarthNetMedia and IFC agree as fol

Earthnetmedia Inc – LOCK-UP AGREEMENT (March 29th, 2002)

EXHIBIT 10.6 LOCK-UP AGREEMENT THIS AGREEMENT is entered into on the 10TH day of August, 2001 between EarthNetMedia, Inc., a Nevada Corporation, ("EarthNetMedia" or the "Company") and Ms. Alie Chang and Mr. Felizian Paul, residents of the City of Santa Monica, California (Ms. Chang and Mr. Paul hereinafter referred to as the "Shareholders"). WITNESSETH: WHEREAS, EarthnetMedia has filed Form SB-2 by which the Company will offer to sell 100,000 Units to the public, and WHEREAS, a Units consists of one share of Common Stock and forty Common Stock Purchase Warrants, and, WHEREAS, the Shareholders hold five million two hundred fifty two thousand (5,252,000) capital common shares of the Company, and WHEREAS, the Shareholders desire to transfer approximately 250,000 shares to certain individuals ("Transfer to Individuals"), NOW THEREFORE, for good

Earthnetmedia Inc – COMMON STOCK PURCHASE WARRANT B (September 14th, 2001)

This Warrant can be exercised on or after__________ . This Warrant will expire if not exercised prior to 3:30 PM Pacific Time on __________ CUSIP ___________ EARTHNETMEDIA, INC. COMMON STOCK PURCHASE WARRANT B THIS CERTIFIES THAT or his/her assignee, is the owner of B Warrants each of which entitles the owner thereof to purchase, during the period commencing from the date of the conclusion of the Offering and expiring at the close of business six months thereafter, one fully paid and non-assessable share of Common Stock, par value $0.001, of EarthNetMedia, Inc., a Nevada Corporation, (hereinafter called the "Company") upon payment of the Warrant price. The Warrant price shall be $1.75 per share. The Warrant Price is payable, upon the exercise of the Warrant. No ad

Earthnetmedia Inc – COMMON STOCK PURCHASE WARRANT D (September 14th, 2001)

This Warrant can be exercised on or after__________ . This Warrant will expire if not exercised prior to 3:30 PM Pacific Time on __________ CUSIP ___________ EARTHNETMEDIA, INC. COMMON STOCK PURCHASE WARRANT D THIS CERTIFIES THAT or his/her assignee, is the owner of D Warrants each of which entitles the owner thereof to purchase, during the period commencing from the date of the conclusion of the Offering and expiring at the close of business twelve months thereafter, one fully paid and non-assessable share of Common Stock, par value $0.001, of EarthNetMedia, Inc., a Nevada Corporation, (hereinafter called the "Company") upon payment of the Warrant price. The Warrant price shall be $2.25 per share. The Warrant Price is payable, upon the exercise of the Warrant. No a

Earthnetmedia Inc – COMMON STOCK PURCHASE WARRANT C (September 14th, 2001)

This Warrant can be exercised on or after __________ . This Warrant will expire if not exercised prior to 3:30 PM Pacific Time on __________ CUSIP ___________ EARTHNETMEDIA, INC. COMMON STOCK PURCHASE WARRANT C THIS CERTIFIES THAT or his/her assignee, is the owner of C Warrants each of which entitles the owner thereof to purchase, during the period commencing from the date of the conclusion of the Offering and expiring at the close of business nine months thereafter, one fully paid and non-assessable share of Common Stock, par value $0.001, of EarthNetMedia, Inc., a Nevada Corporation, (hereinafter called the "Company") upon payment of the Warrant price. The Warrant price shall be $2.00 per share. The Warrant Price is payable, upon the exercise of the Warrant. No a

Earthnetmedia Inc – COMMON STOCK PURCHASE WARRANT A (September 14th, 2001)

This Warrant can be exercised on or after __________ . This Warrant will expire if not exercised prior to 3:30 PM Pacific Time on __________ CUSIP ___________ EARTHNETMEDIA, INC. COMMON STOCK PURCHASE WARRANT A THIS CERTIFIES THAT or his/her assignee, is the owner of A Warrants each of which entitles the owner thereof to purchase, during the period commencing from the date of the conclusion of the Offering and expiring at the close of business three months thereafter, one fully paid and non-assessable share of Common Stock, par value $0.001, of EarthNetMedia, Inc., a Nevada Corporation, (hereinafter called the "Company") upon payment of the Warrant price. The Warrant price shall be $1.50 per share. The Warrant Price is payable, upon the exercise of the Warrant. No ad

Earthnetmedia Inc – AGREEMENT (June 29th, 2001)

AGREEMENT Party A: Beijing Television Station, Economic Information Department "Home Sweet Home" Program. Party B: EarthNetMedia Inc. of United States Beijing Television Station, Economic Information Department "Home Sweet Home" is a television program oriented to home improvement, decoration, building material and real estate development. In this program the latest international building technology will be introduced to our television audience. Through negotiation both parties agree to sign the following agreement for collaboration: I. THE PURPOSE OF COLLABORATION: Within the "home Sweet Home" program each week a 3 to 5 minutes segment of television program will be provided by US designer Alie Chang. The content of the program should be mutually agreed and it should be based on the concept and theory on interior design as well as introduce the latest international building material and home decoration and accessories products. II THE ME

Earthnetmedia Inc – EMPLOYMENT AGREEMENT (June 29th, 2001)

EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT dated as of January 1, 2001 is by and between EarthNetMedia, Incorporated a Nevada corporation, 222 Amalfi Drive, Santa Monica, CA 90402 (the "Company") and Alie Chang, an individual presently residing at 222 Amalfi Dr. Santa Monica, California (the "Employee"). RECITALS: A. The Employee is critical to the long-term viability and success of the Company. B. The Employee desires to be employed by the Company and the Company desires to retain the Employee on the terms and conditions set forth herein. AGREEMENTS: The parties hereto, in consideration of the covenants and agreements set forth herein and other good and valuable consideration, agree as follows: 1.DEFINITIONS. For purposes of this Agreement, the following terms shall have the meaning indicated: 1.1 Board means the Board of Directors of the Company or any successor thereof. 1.2 Company means Ear

Earthnetmedia Inc – EMPLOYMENT AGREEMENT (June 29th, 2001)

EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT dated as of January 12, 2001 is by and between EarthNetMedia, Incorporated a Nevada corporation, 222 Amalfi Drive, Santa Monica, CA 90402 (the "Company") and Marvin S. Berger, an individual presently residing at xxxxx (the "Employee"). RECITALS: A. The Employee is critical to the long-term viability and success of the Company. B. The Employee desires to be employed by the Company and the Company desires to retain the Employee on the terms and conditions set forth herein. AGREEMENTS: The parties hereto, in consideration of the covenants and agreements set forth herein and other good and valuable consideration, agree as follows: 1. DEFINITIONS. For purposes of this Agreement, the following terms shall have the meaning indicated: 1.1 Board means the Board of Directors of the Company or any successor thereof. 1.2 Company means EarthNetMedia, Incorporated or

Earthnetmedia Inc – COMMON STOCK PURCHASE WARRANT C (June 29th, 2001)

This Warrant will be void if not exercised prior to 3 30 p.m. Los Angeles time on __________ CUSIP ___________ EARTHNETMEDIA, INC. COMMON STOCK PURCHASE WARRANT C THIS CERTIFIES THAT or registered assigns, is the owner of WARRANTS each of which entitles the owner thereof to purchase, during the period commencing from conclusion of the Underwriting and expiring at the close of business nine months thereafter, one fully paid and non-assessable share of Common Stock, par value $0.001, of EarthNetMedia, Inc., a Nevada Corporation, (hereinafter called the "Company") upon payment of the Warrant price: provided, however that the number of shares of the Company's Common Stock purchasable upon the exercise of this Warrant may be increased or reduced and the Warr

Earthnetmedia Inc – MEMORANDUM OF UNDERSTANDING OF CORPORATION (June 29th, 2001)

MEMORANDUM OF UNDERSTANDING OF CORPORATION PARTY A: EarthNetMedia Inc, of the United States PARTY B: Beijing BETC Advertising Ltd. Both parties agree to produce and distribute this television program concerning interior design and home improvement, and we have agreed upon the following items and areas of cooperation - the length of the program will be 30 minutes. There will be 52 episodes yearly. Party A 1. Based on the proposed guidelines provided by Party B, Party A is responsible for all camera shooting and material preparation, scripts, etc. in the United States, and International Territories (not including China) 2. Party A guarantees the timely delivery of the completed program on broad- casting tapes. 3. All the material and the tapes provided are required to meet the broadcast- ing standard of the Chinese Ministry of Television and Radio Broadcasting 4. Based on the segment standards agreed to by both parties, Party A is